Inovio Pharmaceuticals is engaged in the development of synthetic vaccines, with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of universal vaccines capable of providing cross-protection against pathogens, such as influenza and human immunodeficiency virus (HIV). INO’s clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. For further information, visit the company’s Web site at www.inovio.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: